Exploiting Carbon Monoxide Biofoams to Radio-Sensitize Rectal Cancer Cells While Protecting Normal Bowel
利用一氧化碳生物泡沫对直肠癌细胞放射增敏,同时保护正常肠道
基本信息
- 批准号:10572013
- 负责人:
- 金额:$ 25.32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-06-09 至 2028-05-31
- 项目状态:未结题
- 来源:
- 关键词:AcuteAdjuvant TherapyAntioxidantsAntitumor ResponseBiochemicalBiocompatible MaterialsBiologyCancer BiologyCancer PatientCarbon MonoxideCatabolismCell RespirationCell SurvivalCellsCellular biologyChronicColorectal CancerCombination Drug TherapyCytoprotectionDiagnosisDoseDoxycyclineEnvironmentEpithelial CellsEvaluationExcisionExposure toFormulationFree RadicalsGastrointestinal tract structureGenesGeneticGoalsHemeHydrogen PeroxideIn VitroIncidenceIndividualInflammationInhalationInternationalIntestinesIowaKnockout MiceLeadMalignant NeoplasmsMentorsMetabolicMethodologyMethodsMitochondriaModelingMolecularMolecular BiologyMusNeoadjuvant TherapyNormal CellNormal tissue morphologyOperative Surgical ProceduresOxidation-ReductionOxidative StressOxidative Stress InductionPathologic ProcessesPathway interactionsPhysiciansPhysiological ProcessesPositioning AttributeProctitisProductionPropertyQuality of lifeQuantitative EvaluationsRadiationRadiation ToleranceRadiosensitizationRectal CancerRectumRegimenResearchRoleScientistSeverity of illnessSignal TransductionStressSuperoxidesTestingTherapeuticTissuesTrainingTranslatingTranslationsTumor BurdenTumor TissueUnited StatesUniversitiesWorkanti-cancerantioxidant enzymeantitumor effectbiological adaptation to stressbiomaterial developmentcancer cellcell killingchemoradiationenzyme pathwaygastrointestinalheme oxygenase-1improvedimproved outcomein vivointestinal epitheliummimeticsmouse modelneoplastic cellnovelnovel therapeuticsoxidative damagepharmacologicpreservationradiation responserectalresponseskillstissue injurytooltranscription factortranslational therapeutics
项目摘要
ABSTRACT
An estimated 45,230 individuals were diagnosed with rectal cancer in the United States in 2021. Rectal cancer
is primarily managed using a combination of chemotherapy, radiation, and surgery. Surgical resection of the
rectum is associated with long-term functional deficits and decreased quality-of-life. Therefore, strategies to
improve response to neoadjuvant chemoradiotherapy could increase non-surgical curative rates and enhance
quality-of-life for rectal cancer patients. Carbon monoxide (CO) at low, non-toxic concentrations has been shown
to provide paradoxical anti-tumor effects while inhibiting inflammation and oxidative-stress induced normal tissue
injury that could serve as an adjuvant treatment to enhance chemo-radiotherapy efficacy. CO is a product of
heme catabolism regulated by the Nrf2 transcription factor and the cytoprotective gene Heme Oxygenase-1 (HO-
1). The biochemical mechanisms by which CO simultaneously sensitizes tumor cells to die while preserving
normal cell survival are unknown but likely involve fundamental differences in oxidative metabolism between
cancer and normal cells. Identifying targetable redox sensitive mechanisms underlying the activity of CO in rectal
cancer could rapidly lead to translational therapeutic approaches for improving radiation responses in cancers
while limiting normal tissue injury. We have developed exciting new methods for CO delivery through the
gastrointestinal (GI) tract to overcome the challenges of inhaled CO. Using these GI formulations to deliver CO,
our central hypothesis is that CO, delivered as a safe biofoam, selectively chemo-radio-sensitizes rectal
cancer while reducing normal tissue injury. Further that the mechanism involves differential effects on
Nrf2/HO-1 signaling and modulation of mitochondrial oxidative metabolism. We will evaluate the impact of
cytoprotective CO biofoams on normal rectal tissue responses and oxidative damage after exposure to
chemoradiotherapy and determine the effects of CO as an adjunct to therapy for rectal cancer in mice.
摘要
据估计,2021年美国有45230人被诊断患有直肠癌。直肠癌
主要使用化疗、放射治疗和手术相结合的方法进行治疗。外科手术切除眼球
直肠与长期的功能缺陷和生活质量下降有关。因此,应采取以下策略
改善对新辅助放化疗的反应可以提高非手术治愈率和
直肠癌患者的生活质量。一氧化碳(CO)已被证明在低浓度、无毒
在抑制炎症和氧化应激诱导的正常组织的同时提供矛盾的抗肿瘤作用
可作为辅助治疗以提高放化疗疗效的损伤。CO是一种产品
Nrf2转录因子和细胞保护基因HO-1对血红素分解代谢的调节
1)。一氧化碳使肿瘤细胞在保存的同时敏化死亡的生化机制
正常的细胞存活尚不清楚,但可能涉及氧化代谢的根本差异
癌症和正常细胞。确定直肠一氧化碳活性的靶向氧化还原敏感机制
癌症可以迅速带来改善癌症放射反应的转化性治疗方法
同时限制正常组织损伤。我们已经开发出令人振奋的新方法,通过
胃肠道(GI)克服吸入一氧化碳的挑战。使用这些GI配方来输送CO,
我们的中心假设是,CO作为一种安全的生物泡沫输送,选择性地使直肠具有化学-放射敏感性
癌症的同时减少对正常组织的损伤。此外,该机制涉及对
NRF2/HO-1信号转导与线粒体氧化代谢的调控我们将评估这些措施的影响
细胞保护性CO生物泡沫暴露后对正常直肠组织反应和氧化损伤的影响
化疗和放射治疗,并确定一氧化碳作为治疗直肠癌的辅助治疗小鼠的效果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
James Donald Byrne其他文献
James Donald Byrne的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 25.32万 - 项目类别:
The ESCAPE clinical trial of circulating tumor DNA to guide adjuvant therapy in chemo-resistant triple negative breast cancer
循环肿瘤 DNA 指导化疗耐药三阴性乳腺癌辅助治疗的 ESCAPE 临床试验
- 批准号:
494901 - 财政年份:2023
- 资助金额:
$ 25.32万 - 项目类别:
Operating Grants
A Type I Hybrid Effectiveness-Implementation Trial to Evaluate a Navigation-Based Multilevel Intervention to Decrease Delays Starting Adjuvant Therapy Among Patients with Head and Neck Cancer
一项 I 型混合有效性实施试验,用于评估基于导航的多级干预措施,以减少头颈癌患者开始辅助治疗的延迟
- 批准号:
10714537 - 财政年份:2023
- 资助金额:
$ 25.32万 - 项目类别:
Multi-modal machine learning to guide adjuvant therapy in surgically resectable colorectal cancer
多模式机器学习指导可手术切除结直肠癌的辅助治疗
- 批准号:
10588103 - 财政年份:2023
- 资助金额:
$ 25.32万 - 项目类别:
Efficacy of ethanol adjuvant therapy after resection of malignant soft tissue tumors
恶性软组织肿瘤切除术后乙醇辅助治疗的疗效
- 批准号:
22K09407 - 财政年份:2022
- 资助金额:
$ 25.32万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of immune response cells and development of novel adjuvant therapy for sublingual immunotherapy
免疫应答细胞的鉴定和舌下免疫治疗新型辅助疗法的开发
- 批准号:
21KK0287 - 财政年份:2022
- 资助金额:
$ 25.32万 - 项目类别:
Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
Pursuing molecular biomarkers to guide adjuvant therapy for HPV+ head and neck cancers after transoral robotic surgery
寻找分子生物标志物来指导经口机器人手术后 HPV 头颈癌的辅助治疗
- 批准号:
10357120 - 财政年份:2022
- 资助金额:
$ 25.32万 - 项目类别:
Biomarker research using two prospective studies on preoperative and postoperative adjuvant therapy for pancreatic cancer
使用两项关于胰腺癌术前和术后辅助治疗的前瞻性研究进行生物标志物研究
- 批准号:
21K08700 - 财政年份:2021
- 资助金额:
$ 25.32万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Personalized Resistant Starch as an Adjuvant Therapy for Pediatric Inflammatory Bowel Disease
个性化抗性淀粉作为小儿炎症性肠病的辅助治疗
- 批准号:
437315 - 财政年份:2020
- 资助金额:
$ 25.32万 - 项目类别:
Studentship Programs
Tailored adjuvant therapy in POLE-mutated and p53-wildtype early stage endometrial cancer (TAPER)
POLE 突变和 p53 野生型早期子宫内膜癌 (TAPER) 的定制辅助治疗
- 批准号:
435603 - 财政年份:2020
- 资助金额:
$ 25.32万 - 项目类别:
Operating Grants